Hence blocking of FGF19/FGFR4 axis by ponatinib, a third-generation tyrosine–kinase inhibitor, could overcome the resistance of HCC cells to sorafenib [83]. The gene discussed is FGFR4; the disease is hepatocellular carcinoma.